{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:28:20Z","timestamp":1790803700666,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005617","name":"BHF Centre of Research Excellence, Oxford","doi-asserted-by":"publisher","award":["P30 DK072482"],"award-info":[{"award-number":["P30 DK072482"]}],"id":[{"id":"10.13039\/501100005617","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005617","name":"BHF Centre of Research Excellence, Oxford","doi-asserted-by":"publisher","award":["UL1 TR003098"],"award-info":[{"award-number":["UL1 TR003098"]}],"id":[{"id":"10.13039\/501100005617","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jcf.2023.10.010","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T07:20:43Z","timestamp":1697268043000},"page":"155-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Effect of elexacaftor\/tezacaftor\/ivacaftor on mucus and mucociliary clearance in cystic fibrosis"],"prefix":"10.1016","volume":"23","author":[{"given":"Scott H.","family":"Donaldson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy E.","family":"Corcoran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Pilewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mogayzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth L.","family":"Laube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan R.","family":"Boitet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elex S.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Ceppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd J.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirby","family":"Zeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R.","family":"Esther Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2023.10.010_bib0001","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2023.10.010_bib0002","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2023.10.010_bib0003","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2023.10.010_bib0004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of promise-GI","author":"Schwarzenberg","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.10.010_bib0005","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jcf.2021.02.003","article-title":"PROMISE: working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy","volume":"20","author":"Nichols","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.10.010_bib0006","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122695","article-title":"Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR","volume":"3","author":"Donaldson","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcf.2023.10.010_bib0007","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jcf.2021.05.004","article-title":"Effect of lumacaftor-ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis: results from the PROSPECT MCC sub-study","volume":"21","author":"Donaldson","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.10.010_bib0008","doi-asserted-by":"crossref","first-page":"L398","DOI":"10.1152\/ajplung.00398.2016","article-title":"Sialic acid-to-urea ratio as a measure of airway surface hydration","volume":"312","author":"Esther","year":"2017","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jcf.2023.10.010_bib0009","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the cystic fibrosis questionnaire-revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2023.10.010_bib0010","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1164\/ajrccm.164.8.2104075","article-title":"Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction","volume":"164","author":"Sagel","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2023.10.010_bib0011","doi-asserted-by":"crossref","DOI":"10.1172\/JCI73469","article-title":"Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure","author":"Henderson","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2023.10.010_bib0012","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.chest.2018.03.005","article-title":"Cystic fibrosis sputum rheology correlates with both acute and longitudinal changes in lung function","volume":"154","author":"Ma","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2023.10.010_bib0013","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.125954","article-title":"A glycopolymer improves vascoelasticity and mucociliary transport of abnormal cystic fibrosis mucus","volume":"4","author":"Fernandez-Petty","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcf.2023.10.010_bib0014","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1183\/09031936.03.00038803","article-title":"Exhaled breath condensate pH is a robust and reproducible assay of airway acidity","volume":"22","author":"Vaughan","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2023.10.010_bib0015","doi-asserted-by":"crossref","first-page":"L504","DOI":"10.1152\/ajplung.00344.2012","article-title":"Exhaled breath condensate adenosine tracks lung function changes in cystic fibrosis","volume":"304","author":"Esther","year":"2013","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jcf.2023.10.010_bib0016","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa043891","article-title":"Mucus clearance and lung function in cystic fibrosis with hypertonic saline","volume":"354","author":"Donaldson","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2023.10.010_bib0017","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.chest.2021.10.049","article-title":"Identification of sputum biomarkers predictive of pulmonary exacerbations in COPD","volume":"161","author":"Esther","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2023.10.010_bib0018","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2023.10.010_bib0019","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2023.10.010_bib0020","doi-asserted-by":"crossref","DOI":"10.3791\/63876-v","article-title":"Rapid viscoelastic characterization of airway mucus using a benchtop rheometer","author":"Wykoff","year":"2022","journal-title":"J Vis Exp"},{"key":"10.1016\/j.jcf.2023.10.010_bib0021","first-page":"1","article-title":"Mucus hydration in subjects with stable chronic bronchitis: a comparison of spontaneous and induced sputum","author":"Henderson","year":"2019","journal-title":"COPD"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323009311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323009311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T04:10:31Z","timestamp":1767240631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323009311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1569199323009311"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.10.010","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of elexacaftor\/tezacaftor\/ivacaftor on mucus and mucociliary clearance in cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}